RESUMEN
Defects in cardiac contractility and heart failure (HF) are common following doxorubicin (DOX) administration. Different miRs play a role in HF, and their targeting was suggested as a promising therapy. We aimed to target miR-24, a suppressor upstream of junctophilin-2 (JP-2), which is required to affix the sarcoplasmic reticulum to T-tubules, and hence the release of Ca2+ in excitation-contraction coupling using pachymic acid (PA) and/or losartan (LN). HF was induced with DOX (3.5 mg/kg, i.p., six doses, twice weekly) in 24 rats. PA and LN (10 mg/kg, daily) were administered orally for four weeks starting the next day of the last DOX dose. Echocardiography, left ventricle (LV) biochemical and histological assessment and electron microscopy were conducted. DOX increased serum BNP, HW/TL, HW/BW, mitochondrial number/size and LV expression of miR-24 but decreased EF, cardiomyocyte fiber diameter, LV content of JP-2 and ryanodine receptors-2 (RyR2). Treatment with either PA or LN reversed these changes. Combined PA + LN attained better results than monotherapies. In conclusion, HF progression following DOX administration can be prevented or even delayed by targeting miR-24 and its downstream JP-2. Our results, therefore, suggest the possibility of using PA alone or as an adjuvant therapy with LN to attain better management of HF patients, especially those who developed tolerance toward LN.
Asunto(s)
Doxorrubicina/efectos adversos , Regulación de la Expresión Génica , Insuficiencia Cardíaca/etiología , Proteínas de la Membrana/genética , MicroARNs/genética , Triterpenos/farmacología , Animales , Cardiomegalia/diagnóstico , Cardiomegalia/tratamiento farmacológico , Cardiomegalia/etiología , Cardiomegalia/metabolismo , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/metabolismo , Pruebas de Función Cardíaca , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Miocitos Cardíacos/ultraestructura , Ratas , Canal Liberador de Calcio Receptor de Rianodina/metabolismo , Transducción de SeñalRESUMEN
Postmenopausal women are at an increased risk of vascular calcification which is defined as the pathological deposition of minerals in the vasculature, and is strongly linked with increased cardiovascular disease risk. Since estrogen-replacement therapy is associated with increased cancer risk, there is a strong need for safer therapeutic approaches. In this study we aimed to investigate the protective and therapeutic effects of the phytoestrogen resveratrol against vascular calcification in ovariectomized rats, a preclinical model of postmenopause. Furthermore, we aimed to compare the effects of resveratrol to those of estrogen and to explore the mechanisms underpinning those effects. Treatment with resveratrol or estrogen ameliorated aortic calcification in ovariectomized rats, as shown by reduced calcium deposition in the arterial wall. Mechanistically, the effects of resveratrol and estrogen were mediated via the activation of SIRT1 signaling. SIRT1 protein expression was downregulated in the aortas of ovariectomized rats, and upregulated in rats treated with resveratrol or estrogen. Moreover, resveratrol and estrogen reduced the levels of the osteogenic markers: runt-related transcription factor 2 (RUNX2), osteocalcin and alkaline phosphatase (ALP) which have been shown to play a role during vascular calcification. Additionally, the senescence markers (p53, p16 and p21) which were also reported to play a role in the pathogenesis of vascular calcification, were reduced upon treatment with resveratrol and estrogen. In conclusion, the phytoestrogen resveratrol may be a safer alternative to estrogen, as a therapeutic approach against the progression of vascular calcification during postmenopause.
Asunto(s)
Subunidad alfa 1 del Factor de Unión al Sitio Principal/metabolismo , Fitoestrógenos/farmacología , Resveratrol/farmacología , Transducción de Señal , Sirtuina 1/metabolismo , Calcificación Vascular/tratamiento farmacológico , Animales , Aorta/efectos de los fármacos , Aorta/patología , Subunidad alfa 1 del Factor de Unión al Sitio Principal/genética , Femenino , Osteogénesis/efectos de los fármacos , Ovariectomía , Posmenopausia , Ratas , Sirtuina 1/genética , Calcificación Vascular/patologíaRESUMEN
Increased fructose consumption is among bad nutritional habits that contribute to increased incidence of neurodegenerative diseases. We proposed that coffee, the most popular beverage worldwide, may protect against the progression of Alzheimer's disease (AD). We investigated the protective potential of decaffeinated green coffee bean extract (GCBE) and the possible potentiation of pioglitazone (PIO) effects by decaffeinated GCBE in fructose-induced AD in rats. Twenty-four rats [12-untreated and 12-pre-treated (for 4 weeks) with GCBE] consumed drinking water supplemented with 10% fructose for 18 weeks. Twelve of these rats (6-GCBE-untreated and 6-GCBE-pre-treated) were treated orally with PIO starting on the 13th week for 6 weeks. Prophylactic administration of GCBE attenuated oxidative damage (increased cortical reduced glutathione and superoxide dismutase activity), while decreased malondialdehyde. It retarded the activation of acetylcholine esterase, increased acetylcholine level in the cortex of fructose-induced AD. It also impeded the upregulation of beta-secretase-1and the accumulation of Aß plaques that were induced by fructose drinking. With PIO therapy, GCBE showed better effects alleviating oxidative stress and Aß extracellular plaques formation, while improving cholinergic activity, learning, and memory ability. In conclusions, the consumption of GCBE may protect against the development of AD and delay the progression of AD when given with PIO. PRACTICAL APPLICATIONS: Decaffeinated dietary supplement of green coffee bean extract attenuated the deleterious consequences of fructose-induced Alzheimer's disease in rats. It improved the antioxidant status and cortical cholinergic activity, while hindered the changes responsible for amyloid plaque formation. It also improved the impaired learning and memory. These results, if confirmed by clinical studies, may recommend the consumption of decaffeinated green coffee beans extract as dietary supplement or as a regular beverage to protect against AD in individuals with family history or early signs of AD. With pioglitazone, such dietary supplement improved pioglitazone efficacy and delayed the progression of AD.
Asunto(s)
Enfermedad de Alzheimer , Enfermedad de Alzheimer/inducido químicamente , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/prevención & control , Animales , Antioxidantes , Café , Fructosa , Pioglitazona , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , RatasRESUMEN
Objective: Alzheimer's disease (AD), a neurodegenerative disorder, involves brain insulin signaling cascades and insulin resistance (IR). Because of limited treatment options, new treatment strategies are mandatory. Green coffee bean extract (GCBE) was reported to attenuate IR and improve brain energy metabolism. We aimed to investigate the possible use of GCBE as a prophylactic strategy to delay the onset of AD or combined with pioglitazone (PIO) as a strategy to retard the progression of AD.Methods: Rats received 10% fructose in drinking water for 18 weeks to induce AD. GCBE-prophylactic group received GCBE for 22 weeks started 4 weeks prior to fructose administration. The PIO group treated with PIO for 6 weeks started on week 12 of fructose administration. The GCBE+PIO group received GCBE for 22 weeks started 4 weeks prior to fructose administration and treated with PIO for the last 6 weeks of fructose administration.Results: Pretreatment with GCBE, either alone or combined with PIO, alleviated IR-induced AD changes. GCBE improved cognition, decreased serine phosphorylation of insulin receptor substrate, increased phosphoinositol-3 kinase (PI3K) activity and protein kinase B (Akt) gene expression, decreased glycogen synthase kinase-3ß (GS3Kß) gene expression and Tau hyperphosphorylation.Discussion: GCBE exerted neuroprotective effects against IR-induced AD mediated by alleviating IR and modulating brain insulin signaling cascade.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Café , Resistencia a la Insulina , Insulina/metabolismo , Fármacos Neuroprotectores/administración & dosificación , Extractos Vegetales/administración & dosificación , Animales , Hipocampo/efectos de los fármacos , Hipocampo/patología , Masculino , Fosfatidilinositol 3-Quinasas/metabolismo , Pioglitazona/administración & dosificación , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas Wistar , Transducción de SeñalAsunto(s)
Celosia , Cálculos Renales/tratamiento farmacológico , Nefrolitiasis/tratamiento farmacológico , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Citrato de Potasio/uso terapéutico , Humanos , Cálculos Renales/sangre , Nefrolitiasis/sangre , Hormona Paratiroidea/sangre , Proyectos Piloto , Preparaciones de Plantas/farmacología , Citrato de Potasio/farmacología , SemillasRESUMEN
New therapies for leukaemia are urgently needed. Carrots have been suggested as a potential treatment for leukaemia in traditional medicine and have previously been studied in other contexts as potential sources of anticancer agents. Indicating that carrots may contain bioactive compounds, which may show potential in leukaemia therapies. This study investigated the effects of five fractions from carrot juice extract (CJE) on human lymphoid leukaemia cell lines, together with five purified bioactive compounds found in Daucus carota L, including: three polyacetylenes (falcarinol, falcarindiol and falcarindiol-3-acetate) and two carotenoids (beta-carotene and lutein). Their effects on induction of apoptosis using Annexin V/PI and Caspase 3 activity assays analysed via flow cytometry and inhibition of cellular proliferation using Cell Titer Glo assay and cell cycle analysis were investigated. Treatment of all three lymphoid leukaemia cell lines with the fraction from carrot extracts which contained polyacetylenes and carotenoids was significantly more cytotoxic than the 4 other fractions. Treatments with purified polyacetylenes also induced apoptosis in a dose and time responsive manner. Moreover, falcarinol and falcarindiol-3-acetate isolated from Daucus carota L were more cytotoxic than falcarindiol. In contrast, the carotenoids showed no significant effect on either apoptosis or cell proliferation in any of the cells investigated. This suggests that polyacetylenes rather than beta-carotene or lutein are the bioactive components found in Daucus carota L and could be useful in the development of new leukemic therapies. Here, for the first time, the cytotoxic effects of polyacetylenes have been shown to be exerted via induction of apoptosis and arrest of cell cycle.
Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Daucus carota/química , Luteína/farmacología , Poliinos/farmacología , beta Caroteno/farmacología , Anexina A5 , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Apoptosis/efectos de los fármacos , Caspasa 3/metabolismo , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Fraccionamiento Químico , Humanos , Leucemia Linfoide/tratamiento farmacológico , Leucemia Linfoide/metabolismo , Luteína/química , Luteína/aislamiento & purificación , Extractos Vegetales/química , Poliinos/química , Poliinos/aislamiento & purificación , Extracción en Fase Sólida , beta Caroteno/química , beta Caroteno/aislamiento & purificaciónRESUMEN
BACKGROUND: Present study aimed to study effect of Salacia Chinensis, a herbal drug, on stabilization of renal functions, and markers of endothelial dysfunction in diabetic chronic kidney disease (CKD) patients. MATERIALS AND METHODS: 30 stable diabetic CKD patients were randomized into 2 groups; group A and B of 15 patients each. Group A was given trial drug Salacia chinensis 1000 mg twice-daily while group B received placebo. Measures of renal function: Serum creatinine and creatinine clearance; markers of endothelial dysfunction: Interleukin-6 and serum Homocysteine, and lipid profile were measured at baseline and during follow-up period of 6 months. RESULTS: There was stabilization of renal function as measured by serum creatinine and creatinine clearance in patients who received Salacia Chinensis compared to placebo (P value < 0.05), suggesting that Salacia chinensis may retard the progression of chronic kidney disease. Similarly, there was significant decline in both serum homocysteine and IL-6 levels. [P value < 0.05 for both]. CONCLUSION: This pilot study showed a promising role for Salacia chinensis as a renoprotective drug, but further prospective studies involving large number of patients are needed to confirm this and also to delineate possible mechanisms.
Asunto(s)
Nefropatías Diabéticas/prevención & control , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Salacia , Adulto , Apolipoproteínas B/sangre , Colesterol/sangre , Creatinina/sangre , Nefropatías Diabéticas/sangre , Nefropatías Diabéticas/fisiopatología , Homocisteína/sangre , Humanos , Interleucina-6/sangre , Masculino , Persona de Mediana Edad , Proyectos Piloto , Triglicéridos/sangreRESUMEN
Trovafloxacin, a new trifluoroquinolone, was evaluated for its therapeutic efficacy against Klebsiella pneumoniae lung infection in tumour (P388 murine leukaemia cells)-bearing mice, treated with or without a chemotherapeutic agent, daunorubicin (DNR) and in mice without tumour. Its activity was compared with ciprofloxacin and cephazolin. The effect on therapeutic efficacy of the addition of recombinant granulocyte colony stimulating factor (rGCSF) was also examined. Our study showed that both quinolones successfully cured pneumonia owing to infection with K. pneumoniae in mice without tumours but that all antibiotics failed in tumour-bearing mice if DNR was withheld. Substantial differences were noted in DNR-treated tumour-bearing mice with infection-the cure rate with trovafloxacin was 91% whereas the cure rate with ciprofloxacin or cephazolin was 57%. Addition of rGCSF to ciprofloxacin did not substantially improve its efficacy (when assessed by protection against death owing to infection; the survival rate was 41%). Trovafloxacin cure rates ranged from 80 to 90% whether or not rGCSF was added to the treatment regimen. Our results suggest that prior cancer chemotherapy had no adverse effect on the therapeutic efficacy of trovafloxacin, and that trovafloxacin may be a promising therapeutic agent for treatment of bacterial infections in the presence of leucopenia.
Asunto(s)
Antiinfecciosos/uso terapéutico , Fluoroquinolonas , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , Leucemia P388/complicaciones , Naftiridinas/uso terapéutico , Neumonía Bacteriana/tratamiento farmacológico , Animales , Antiinfecciosos/farmacocinética , Antibióticos Antineoplásicos/uso terapéutico , Ciprofloxacina/uso terapéutico , Daunorrubicina/uso terapéutico , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/metabolismo , Klebsiella pneumoniae/metabolismo , Leucemia P388/tratamiento farmacológico , Leucemia P388/metabolismo , Recuento de Leucocitos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos DBA , Naftiridinas/farmacocinética , Trasplante de Neoplasias , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/metabolismo , Proteínas RecombinantesRESUMEN
In Patan Hospital, Kathmandu, 4600 single live births were analysed concerning birth weight in relation to gestational age. At term, the median birth weight of females was 2900 g and of males 3010 g. Compared with Norwegian newborns, the birthweights of Nepali babies were lower for all corresponding gestational lengths. The differences increased with gestational age. Fundal height was lower in Nepali than in Norwegian pregnant women for all periods of pregnancy. An increase in the differences between Norwegian and Nepali women was also noted. Hematocrit values of Nepali women who did not take supplementary iron, correspond well to findings in Norwegian women without iron supplementation. Only a slight degree of hemoconcentration was noted towards term. For Norwegian women with iron supplementation the hematocrit values were much higher, with a tendency towards hemoconcentration near term. In Nepal the average woman probably has small iron stores, and without iron supplementation the hematocrit values will remain low throughout the pregnancy. The high altitude does not seem to cause hemoconcentration in pregnancy to a greater extent than at lower altitude. Hemoconcentration is therefore not a major causative factor of the lower birth weights.
PIP: The association between birthweight and gestational age was examined in 4600 singleton live births occurring at Patan Hospital (Kathmandu, Nepal) in 1983-86. Other parameters evaluated included fundal height in relationship to duration of pregnancy and hematocrit levels during pregnancy. The study results were then compared to similar data from Norway. At term, the median birth weight in Nepal in this series was 3010 grams for males and 2900 grams for females. Although the birthweights of Norwegian infants are consistently higher than those of Nepalese infants, this difference is most pronounced after the 36th week of pregnancy. Fundal height shows a steady, almost linear increase in Nepalese infants until the 37th week of pregnancy, at which point it slows down. In general, fundal height is lower in Nepalese than Norwegian women and this gap widens after 36 weeks of pregnancy. Finally, hematocrit values are generally lower in Nepalese women than Norwegian women, regardless of whether iron supplements are provided. Nepalese women further demonstrated a lack of hemoconcentration during the last 8 weeks of pregnancy, indicating that maternal iron stores had been depleted. The findings of this study are useful for establishing standards for weight for gestational age, fundal height, and hematocrit values in relation to stage of pregnancy in hospital deliveries in Nepal. They suggest, moreover, that Nepalese women suffer from nutritional deficiencies that require further research.